Related Experiment Video
Updated: Jun 29, 2025
Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
Published on: June 16, 2023
Targeting Solute Carrier Transporters (SLCs) as a Therapeutic Target in Different Cancers
Ravi Bharadwaj1, Swati Jaiswal1, Erandi E Velarde de la Cruz2
1Department of Infectious Diseases, UMass Chan Medical School, Worcester, MA 01605, USA.
Abstract:
Solute carrier (SLC) transporters constitute a vast superfamily of transmembrane proteins tasked with regulating the transport of various substances such as metabolites, nutrients, ions, and drugs across cellular membranes. SLC transporters exhibit coordinated expression patterns across normal tissues, suggesting a tightly regulated regulatory network governing normal cellular functions. These transporters are crucial for the transport of various metabolites, including carbohydrates, proteins, lipids, and nucleic acids. However, during tumor development, metabolic changes drive an increased demand for energy and nutrients. Consequently, tumor cells alter the expression of SLC transporters to meet their heightened nutrient requirements. Targeting SLCs through inhibition or activation presents a promising therapeutic approach in cancer treatment. Certain SLCs also serve as intriguing chemo-sensitizing targets, as modulating their activity can potentially alter the response to chemotherapy. This review underscores the significance of various SLCs in tumor progression and underscores their potential as both direct and indirect targets for cancer therapy.
Insights
Solute carrier (SLC) transporters are vital for cell function but are altered in cancer. Targeting these transporters offers a promising strategy for novel cancer therapies and improving chemotherapy response.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Solute carrier (SLC) transporters are transmembrane proteins crucial for cellular transport of metabolites, nutrients, ions, and drugs.
- Normal tissue expression of SLCs suggests a regulated network vital for cellular functions.
- Tumorigenesis involves metabolic reprogramming, increasing nutrient and energy demands.
Purpose of the Study:
- To review the significance of SLC transporters in tumor progression.
- To explore the potential of SLCs as therapeutic targets in cancer treatment.
- To highlight SLCs as chemo-sensitizing targets.
Main Methods:
- Literature review of SLC transporter roles in cancer.
- Analysis of SLC expression patterns in normal versus tumor tissues.
- Evaluation of therapeutic strategies targeting SLCs.
Main Results:
- Tumor cells upregulate specific SLC transporters to meet heightened metabolic needs.
- Targeting SLCs via inhibition or activation shows therapeutic promise in oncology.
- Modulating SLC activity can potentially enhance patient response to chemotherapy.
Conclusions:
- SLC transporters play a critical role in cancer progression.
- SLCs represent promising direct and indirect therapeutic targets for cancer treatment.
- Further research into SLCs could lead to novel cancer therapies.
More Related Videos
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
07:10Author Spotlight: Expression and Purification of Human Solute Carrier Transporters Using Codon-Optimized Genes
Published on: September 29, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:31Membrane Transporters
Transporters are mainly composed of alpha-helices, built from bundles of ten or more helices traversing the plasma membrane. The solute-binding sites are located midway, where some of the helices are broken or distorted, making space for the binding site through...
01:06Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:32Secondary Active Transport
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...